



MEDICAL COVERAGE GUIDELINES
SECTION: SURGERY

ORIGINAL EFFECTIVE DATE: 08/01/17
LAST REVIEW DATE: 08/21/18
LAST CRITERIA REVISION DATE: 12/12/17
ARCHIVE DATE:

CRYOSURGICAL ABLATION OF MISCELLANEOUS SOLID TUMORS OTHER THAN LIVER, PROSTATE OR DERMATOLOGIC TUMORS

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage Guideline must be read in its entirety to determine coverage eligibility, if any.

This Medical Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exceptions to these guidelines.

The section identified as "Description" defines or describes a service, procedure, medical device or drug and is in no way intended as a statement of medical necessity and/or coverage.

The section identified as "Criteria" defines criteria to determine whether a service, procedure, medical device or drug is considered medically necessary or experimental or investigational.

State or federal mandates, e.g., FEP program, may dictate that any drug, device or biological product approved by the U.S. Food and Drug Administration (FDA) may not be considered experimental or investigational and thus the drug, device or biological product may be assessed only on the basis of medical necessity.

Medical Coverage Guidelines are subject to change as new information becomes available.

For purposes of this Medical Coverage Guideline, the terms "experimental" and "investigational" are considered to be interchangeable.

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.



MEDICAL COVERAGE GUIDELINES
SECTION: SURGERY

ORIGINAL EFFECTIVE DATE: 08/01/17
LAST REVIEW DATE: 08/21/18
LAST CRITERIA REVISION DATE: 12/12/17
ARCHIVE DATE:

CRYOSURGICAL ABLATION OF MISCELLANEOUS SOLID TUMORS OTHER THAN LIVER, PROSTATE OR DERMATOLOGIC TUMORS (cont.)

Description:

Cryosurgical Ablation:

A probe is inserted into a tumor to deliver a coolant which causes cell death by freezing the tumor tissue. Cryoablation may be performed as an open procedure or under laparoscopic or ultrasound guidance.

Renal Cell Carcinoma:

Cancer of the lining of the renal (kidney) tubules.

Renal Carcinoma:

Cancer that forms in the center of the kidney.

Criteria:

- Cryosurgical ablation to treat localized renal cell carcinoma that is no more than 4 cm in size is considered **medically necessary** with documentation of **ONE** of the following:
 1. Preservation of kidney function is necessary (i.e., individual has one kidney or renal insufficiency defined by a glomerular filtration rate [GFR] of less than 60 mL/min/m²) and standard surgical approach (i.e., resection of renal tissue) is likely to substantially worsen kidney function
 2. Individual is not considered a surgical candidate

- Cryosurgical ablation to treat lung cancer is considered **medically necessary** with documentation of **ONE** of the following:
 1. Individual has early-stage non-small cell lung cancer (stage I and stage II) and is a poor surgical candidate
 2. Individual requires palliation for a central airway obstructing lesion



MEDICAL COVERAGE GUIDELINES
SECTION: SURGERY

ORIGINAL EFFECTIVE DATE: 08/01/17
LAST REVIEW DATE: 08/21/18
LAST CRITERIA REVISION DATE: 12/12/17
ARCHIVE DATE:

CRYOSURGICAL ABLATION OF MISCELLANEOUS SOLID TUMORS OTHER THAN LIVER, PROSTATE OR DERMATOLOGIC TUMORS (cont.)

Criteria: (cont.)

- Cryosurgical ablation for the following indications or if above criteria not met is considered ***experimental or investigational*** based upon:
1. Insufficient scientific evidence to permit conclusions concerning the effect on health outcomes, and
 2. Insufficient evidence to support improvement of the net health outcome, and
 3. Insufficient evidence to support improvement of the net health outcome as much as, or more than, established alternatives.

These indications include, *but are not limited to:*

- Breast cancer
- Breast fibroadenoma
- Benign lung tumors
- Benign or malignant pancreatic tumors
- Benign or malignant bone tumors
- Other solid tumors or metastases outside the liver and prostate (e.g., adrenal cancer, chordomas, head and neck cancer)

Resources:

Literature reviewed 08/21/18. We do not include marketing materials, poster boards and non-published literature in our review.

The BCBS Association Medical Policy Reference Manual (MPRM) policy is included in our guideline review. References cited in the MPRM policy are not duplicated on this guideline.

Resources prior to 08/21/13 may be requested from the BCBSAZ Medical Policy and Technology Research Department.

1. 7.01.92 BCBS Association Medical Policy Reference Manual. Cryosurgical Ablation of Miscellaneous Solid Tumors Other Than Liver, Prostate, or Dermatologic Tumors. Re-issue date 07/12/2018, issue date 10/09/2003.
2. Colak E, Tatli S, Shyn PB, Tuncali K, Silverman SG. CT-guided percutaneous cryoablation of central lung tumors. *Diagn Interv Radiol*. Jul-Aug 2014;20(4):316-322.



MEDICAL COVERAGE GUIDELINES
SECTION: SURGERY

ORIGINAL EFFECTIVE DATE: 08/01/17
LAST REVIEW DATE: 08/21/18
LAST CRITERIA REVISION DATE: 12/12/17
ARCHIVE DATE:

CRYOSURGICAL ABLATION OF MISCELLANEOUS SOLID TUMORS OTHER THAN LIVER, PROSTATE OR DERMATOLOGIC TUMORS (cont.)

Resources: (cont.)

3. Hahn M, Pavlista D, Danes J, et al. Ultrasound guided cryoablation of fibroadenomas. *Ultraschall Med.* Feb 2013;34(1):64-68.
4. Pruthi S, Jones KN. Nonsurgical management of fibroadenoma and virginal breast hypertrophy. *Semin Plast Surg.* Feb 2013;27(1):62-66.
5. American Society of Breast Surgeons. Management of Fibroadenomas of the Breast, Official Statement. 04/29/2008.



MEDICAL COVERAGE GUIDELINES
SECTION: SURGERY

ORIGINAL EFFECTIVE DATE: 08/01/17
LAST REVIEW DATE: 08/21/18
LAST CRITERIA REVISION DATE: 12/12/17
ARCHIVE DATE:

CRYOSURGICAL ABLATION OF MISCELLANEOUS SOLID TUMORS OTHER THAN LIVER, PROSTATE OR DERMATOLOGIC TUMORS (cont.)

Non-Discrimination Statement:

Blue Cross Blue Shield of Arizona (BCBSAZ) complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability or sex. BCBSAZ provides appropriate free aids and services, such as qualified interpreters and written information in other formats, to people with disabilities to communicate effectively with us. BCBSAZ also provides free language services to people whose primary language is not English, such as qualified interpreters and information written in other languages. If you need these services, call (602) 864-4884 for Spanish and (877) 475-4799 for all other languages and other aids and services.

If you believe that BCBSAZ has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability or sex, you can file a grievance with: BCBSAZ's Civil Rights Coordinator, Attn: Civil Rights Coordinator, Blue Cross Blue Shield of Arizona, P.O. Box 13466, Phoenix, AZ 85002-3466, (602) 864-2288, TTY/TDD (602) 864-4823, crc@azblue.com. You can file a grievance in person or by mail or email. If you need help filing a grievance BCBSAZ's Civil Rights Coordinator is available to help you. You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights electronically through the Office for Civil Rights Complaint Portal, available at <https://ocrportal.hhs.gov/ocr/portal/lobby.jsf>, or by mail or phone at: U.S. Department of Health and Human Services, 200 Independence Avenue SW., Room 509F, HHH Building, Washington, DC 20201, 1-800-368-1019, 800-537-7697 (TDD). Complaint forms are available at <http://www.hhs.gov/ocr/office/file/index.html>

Multi-Language Interpreter Services:

Spanish: Si usted, o alguien a quien usted está ayudando, tiene preguntas acerca de Blue Cross Blue Shield of Arizona, tiene derecho a obtener ayuda e información en su idioma sin costo alguno. Para hablar con un intérprete, llame al 602-864-4884.

Navajo: Díí kwe'é atah nilinígíí Blue Cross Blue Shield of Arizona haada yit'éego bina'idilkidgo éí doodago Háida bíjá anilyeedígíí t'áadoo le'é yina'idilkidgo beehaz'áanii hólo díí t'áa hazaadk'ehjí háká a'doowołgo bee haz'ą doo baqah ilinígóó. Ata' halne'ígíí kojį' bich'į' hodilnih 877-475-4799.

Chinese: 如果您, 或是您正在協助的對象, 有關於插入項目的名稱 Blue Cross Blue Shield of Arizona 方面的問題, 您有權利免費以您的母語得到幫助和訊息。洽詢一位翻譯員, 請撥電話 在此插入數字 877-475-4799。

Vietnamese: Nếu quý vị, hay người mà quý vị đang giúp đỡ, có câu hỏi về Blue Cross Blue Shield of Arizona quý vị sẽ có quyền được giúp và có thêm thông tin bằng ngôn ngữ của mình miễn phí. Để nói chuyện với một thông dịch viên, xin gọi 877-475-4799.

Arabic:

إن كان لديك أو لدى شخص تساعد أسئلة بخصوص Blue Cross Blue Shield of Arizona، فلديك الحق في الحصول على المساعدة والمعلومات الضرورية بلغتك من دون أية تكلفة. للتحدث مع مترجم اتصل بـ 877-475-4799.

